

NOBLE 1 Step + Cup™

Step-by-Step Instructions

The Noble 1 Step + Cup™ is an *in vitro* screening test for the rapid detection of multiple drugs in human urine at or above the following cutoff concentration:

THC	11-nor- Δ^9 -Tetrahydrocannabinol-9-carboxylic acid	50 ng/ml
COC	Benzoylcegonine	150 ng/ml
OPI	Morphine	300 ng/ml
MET	d-Methamphetamine	500 ng/ml
AMP	d-Amphetamine	500 ng/ml
BZO	Oxazepam	300 ng/ml
BAR	Secobarbital	300 ng/ml
MTD	Methadone	300 ng/ml
BUPG	Buprenorphine Glucuronide	10 ng/ml
TCA	Nortriptyline	1000 ng/ml
MDMA	3,4-Methylenedioxymethamphetamine	500 ng/ml
OXY	Oxycodone	100 ng/ml
PCP	Phencyclidine	25 ng/ml
PPX	Propoxyphene	300 ng/ml

These tests provide visual qualitative results and are intended for *in vitro* diagnostic use only. The Noble 1 Step + Cup™ is available in double drug analyte dip format. It is intended for prescription point-of-care use and over-the-counter consumer use.

These tests provide only a preliminary test result and are the first step in a two-step process for detecting drugs of abuse in urine. The second step is confirming the results in a certified laboratory. For a quantitative result or to confirm preliminary positive results obtained by the Noble 1 Step + Cup™, a more specific alternative method such as Gas Chromatography/Mass Spectrometry (GC/MS) must be used. Clinical consideration and professional judgment must be applied to any drug of abuse test result, particularly when a preliminary positive result is indicated.

This is a preliminary screening test that detects drug-of-abuse in urine at specified detection levels. To confirm preliminary positive results, a more specific method such as Gas Chromatography/Mass Spectrometry (GC/MS) must be used.

CONTENTS OF KIT

For Testing:

- ✓ 1 Step-by-Step Test Instructions
- ✓ 25 Individually Wrapped Test Lids
- ✓ 25 Specimen Cups






Specimen
Collection
Cup



Individually
Wrapped Test Lid

NOBLE 1 Step + Cup™

Items for Confirmation Testing

<ul style="list-style-type: none">✓ 1 Specimen Bag✓ 2 Identification Labels✓ 1 Mailing Label	 <p>Specimen Bag</p>	 <p>Identification Label</p>	 <p>Mailing Label</p>
--	---	--	--

STORAGE

Store the Noble 1 Step + Cup™ at room temperature 59°F to 86°F (15°C to 30°C).

INSTRUCTION


Step 1.

Collect fresh urine in the specimen cup. Make sure the urine is **above the minimum line.**

Min. Line →



Open foil pouch. Remove test lid from pouch. Discard desiccant.




Step 2.

Twist the lid onto the cup. The cup lid must be closed tightly.

Step 3.

Tilt the cup on its legs to activate the test. **Read test results at 5 minutes. Do not read after 8 minutes.**



5 Minutes

NOBLE 1 Step + Cup™

INTERPRETATION OF RESULTS

Each strip contains two drug tests. C region shows if the test device works properly and is a valid result. T1 region shows result for Test 1. T2 region shows result for Test 2.

For C region:

The appearance of a line indicates a valid result.

No line means an **Invalid** result. If a test strip does not have a line in the C region, test results are **Invalid** for both T1 and T2 on that strip and the test did not work properly.



For T1 and T2 regions:

The appearance of a line indicates a **Negative** result.


Note: **Any test line, even a very faint test line, is considered a negative result.**

No line indicates a **Preliminary Positive** result.


Note: **Any urine with preliminary positive results should be sent to a laboratory for confirmation.**



Example #1: There is a line appearing in both T1 and T2 regions on all test strips. Therefore, it is **Negative** for all tests.



Example #2: There is no line appearing in the T2 region on the third test strip. Therefore, it is **Preliminary Positive** for BZO test. All other tests are **Negative**.



Example #3: There is no line appearing in the C region on the seventh test strip. Therefore, it is **Invalid** for both PCP and PPX tests. All other tests are **Negative**.

NOBLE 1 Step + Cup™

APPROXIMATE DRUG DETECTION TIME TABLE

<u>Illicit Drug</u>	<u>Identifier</u>	<u>Cut-off Level¹</u>	<u>Minimum Detection Time²</u>	<u>Maximum Detection</u>
Marijuana	THC	50 ng/ml	1-3 hours	1-7 days
Cocaine	COC	150 ng/ml	2-6 hours	2-3 days
Opiates	OPI	300 ng/ml	2-6 hours	1-3 days
Methamphetamine	MET	500 ng/ml	4-6 hours	2-3 days
Amphetamine	AMP	500 ng/ml	4-6 hours	2-3 days
Ecstasy	MDMA	500 ng/ml	2-7 hours	2-4 days
Phencyclidine	PCP	25 ng/ml	4-6 hours	7-14 days
Propoxyphene	PPX	300 ng/ml	2-8 hours	2-7 days

<u>Prescription Drug</u>	<u>Identifier</u>	<u>Cut-off Level¹</u>	<u>Minimum Detection Time²</u>	<u>Maximum Detection</u>
Benzodiazepines	BZO	300 ng/ml	2-7 hours	1-4 days
Barbiturates	BAR	300 ng/ml	2-4 hours	1-3 weeks
Methadone	MTD	300 ng/ml	3-8 hours	1-3 days
Buprenorphine	BUPG	10 ng/ml	2-7 hours	1-6 days
Tricyclic Antidepressants	TCA	1000 ng/ml	8-12 hours	2-7 days
Oxycodone	OXY	100 ng/ml	1-3 hours	1-2 days

¹ Cut-off level is the lowest drug concentration in the urine that can be detected by the Noble 1 Step + Cup™.

² Drug clearance rates are dependent on many factors such as frequency of drug use, the amount of drug taken, metabolism rates, and even body fat content.

PROCEDURE FOR CONFIRMATION

The following is the procedure for confirming preliminary positive results:

Step 1:

Make sure the lid is twisted tightly. Place a check mark in the box on both Identification Labels for the drug(s) with preliminary positive result. Place one Identification Label onto the Noble 1 Step + Cup™. Place the other Identification Label below for your record:

<i>Place Identification Label Here</i>
--

Step 2:

Place the labeled Noble 1 Step + Cup™ into the Specimen Bag and seal the bag.

Step 3:

Place specimen into a shipping box and affix the Mailing Label. Drop the shipping box with POSTAGE into any mailbox. Specimen should be mailed within 24 hours of collection.

NOTE: Please call 1-877-836-5713 M-F 8am – 4pm Central Time to request additional Identification Labels and Mailing Labels if needed.

NOBLE 1 Step + Cup™

OBTAIN CONFIRMATION RESULTS

- ❖ Results will be ready 5 to 7 days after the sample is received in our laboratory.
- ❖ Dial 1-877-836-5713 M-F 8am – 4pm Central Time to obtain confirmation result.
- ❖ You will need the identification number to access the confirmation result.

WARNINGS AND PRECAUTIONS

- ❖ For *in vitro* diagnostic use only (not for internal use).
- ❖ The test is for one time use only. It is not reusable.
- ❖ Do not use the Noble 1 Step + Cup™ after the expiration date printed on the pouch.
- ❖ Keep the Noble 1 Step + Cup™ in its original sealed pouch until ready for use. Do not use the test if the pouch is ripped or torn.
- ❖ Certain foods or medications may cause the test to give false results.
- ❖ Contaminated or tainted urine sample may give false results.
- ❖ Send specimen with preliminary positive or uncertain results to a laboratory for confirmation.
- ❖ Urine may contain infectious diseases. Always wear gloves and wash hands with soap after handling.
- ❖ Do not use this test if you are color-blind.

UNDERSTAND THE TEST RESULTS & FOLLOW UP

What is a Preliminary Positive Result?

The Noble 1 Step + Cup™ is a screening test to detect the presence of drugs in human urine. This means that if a drug is present, you will usually get a preliminary positive test result. It is important to send out the specimen to confirm the preliminary positive result. This is because certain foods, supplements, beverages, or medicines can affect the results of the Noble 1 Step + Cup™.

If the test results are preliminary positive, does it mean that you found drugs of abuse?

No. Take no serious actions until you get the laboratory's result. Many factors may cause a false positive result in the home test. A positive test for a prescription drug does not mean that a person is abusing the drug. This is because the test does not indicate acceptable levels compared to abusive levels of prescribed drugs.

This test cannot be used for legal purposes. If you get a preliminary positive test result, you should send the urine to a laboratory to confirm the test result. The confirmation test is called gas chromatography/mass spectrometry or GC/MS.

Many things can affect the accuracy of the tests, including (but not limited to):

- The way you did the test.
- The way you stored the test.
- What the person ate or drank before taking the test.
- Any other prescription or over-the-counter drugs the person may have taken before the test.

Note: Some over-the-counter medications will produce the same test results as illegally-abused amphetamines. Please call 1-877-836-5713 for a complete list of substances or over-the-counter medications which may cross-react with this test.

Where can I get some help?

Consult with a counselor, doctor, or a qualified professional to help you address drug abuse problems. The following organizations provide helpful resources on drug abuse prevention and recovery programs. These resources are for information purposes only.

Alcohol and Drug Information <http://store.samhsa.gov/home> **Community Anti-Drug Coalitions of America** <http://www.cadca.org> **National Institute on Drug Abuse** www.drugabuse.gov

QUESTIONS?

Call 1-877-836-5713 M-F 8am – 4pm Central Time

QUALITY CONTROL

If you work in a laboratory, you should perform quality control testing and read this section. A built-in procedural control is included in the test by using a different antigen/antibody reaction at the control region (C) on each test strip. This control line should always appear regardless of the presence of drug or metabolite. If the control line does not appear, the test device should be discarded. The presence of this control line in the control region serves as 1) verification that sufficient volume is added and 2) that proper flow is obtained.

Good Laboratory Practice recommends the use of control materials to ensure proper device performance. External controls are not provided in the kit. However, they are available from commercial sources and it is recommended that positive and negative controls be used to verify proper test performance. Use the same assay procedure as with a urine specimen. Quality control testing should be performed with each new lot, each new shipment and every thirty days to check storage. Users should follow the appropriate federal, state, and local guidelines concerning the running of external quality controls.

PERFORMANCE CHARACTERISTICS

PRECISION

A study was conducted at two laboratory and one physician offices in an effort to determine the precision of Noble 1 Step + Cup over 12 or more consecutive days. Testing was conducted on the Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methamphetamine, Methylenedioxyamphetamine, Methadone, Opiates, Oxycodone, Phencyclidine, Propoxyphene, and Tricyclic Antidepressants assays by operators using three different lots of product to demonstrate the within-run, between-run and between-operator precision. An identical panel of coded samples, containing drugs at the concentration of ±50% cut-off level was labeled as a blind and tested at each site. The correlation with expected results was >99% across all lots and sites (with a 95% confidence interval).

ACCURACY

The accuracy of the Noble 1 Step + Cup™ was evaluated in comparison to the results from GC/MS or LC/MS analysis. Thirty-six (36) negative drug-free urine samples were collected from volunteer donors and tested with both the Noble 1 Step + Cup™ and the GC/MS or LC/MS method. Of the 36 negative urine samples tested, all were found negative by both methods. Additionally, for each drug test, a minimum of 40 clinical urine samples previously analyzed by GC/MS or LC/MS method with known concentration(s) of drug(s) values were blind labeled and evaluated. The results are summarized below:

Drug Test		GC/MS Neg.	GC/MS < -50%	GC/MS -50% to Cutoff	GC/MS Cutoff to +50%	GC/MS > +50%	% Agreement w/ GC/MS	
							Neg (-)	Pos (+)
THC 50	Pos. (+)	0	0	1	6	35	97.7%	100%
	Neg. (-)	36	2	4	0	0		
COC 150	Pos. (+)	0	0	3	3	37	92.7%	97.6%
	Neg. (-)	36	0	2	1	0		
OPI 300	Pos. (+)	0	0	3	7	34	92.5%	100%
	Neg. (-)	36	0	1	0	0		
MET 500	Pos. (+)	0	0	0	5	67	100%	96.0%
	Neg. (-)	36	2	4	3	0		
AMP 500	Pos. (+)	0	0	2	5	36	95.1%	100%
	Neg. (-)	36	1	2	0	0		
BZO 300	Pos. (+)	0	0	3	4	39	92.5%	100%
	Neg. (-)	36	0	1	0	0		

Drug Test		GC/MS Neg.	GC/MS < -50%	GC/MS -50% to Cutoff	GC/MS Cutoff to +50%	GC/MS > +50%	% Agreement w/ GC/MS	
							Neg (-)	Pos (+)
BAR 300	Pos. (+)	0	0	1	6	33	97.5%	95.1%
	Neg. (-)	36	0	3	2	0		
MTD 300	Pos. (+)	0	0	0	3	36	100%	97.5%
	Neg. (-)	36	0	4	1	0		
BUPG 10	Pos. (+)	0	0	1	4	38	97.5%	97.7%
	Neg. (-)	36	0	3	1	0		
TCA 1000	Pos. (+)	0	0	0	27	11	100%	92.7%
	Neg. (-)	36	0	4	3	0		
MDMA 500	Pos. (+)	0	0	1	3	40	97.5%	97.7%
	Neg. (-)	36	0	3	1	0		
OXY 100	Pos. (+)	0	0	2	6	38	95.2%	100%
	Neg. (-)	36	0	4	0	0		
PCP 25	Pos. (+)	0	0	0	3	36	100%	95.1%
	Neg. (-)	36	0	4	2	0		
PPX 300	Pos. (+)	0	0	2	4	36	95.0%	100%
	Neg. (-)	36	0	2	0	0		

SPECIFICITY

The specificity for the Noble 1 Step + Cup™ was determined by testing various drugs, drug metabolites, structurally related compounds, and other compounds that are likely to be present in urine. All compounds were prepared in drug-free normal human urine. The effect of specimens with various pH (4.5–9) and specific gravity (1.005–1.030) ranges was also evaluated and found not to interfere with Noble 1 Step + Cup™.

The following compounds produced positive results when tested at or above the concentrations listed below.

AMP 500 ng/ml

Compound	ng/ml	Compound	ng/ml
d-Amphetamine	500	Phentermine	1,000
l-Amphetamine	20,000	β-Phenylethylamine	80,000
d,l-3,4-MDA	1,500		

BAR 300 ng/ml

Compound	ng/ml	Compound	ng/ml
Allobarbitol	1,500	Butalbital	300
Alphenal	400	Butethal	400
Amobarbital	1,500	Pentobarbital	400
Aprobarbital	400	Phenobarbital	400
Barbital	400	Secobarbital	300
Butabarbital	400		

BZO 300 ng/ml

Compound	ng/ml	Compound	ng/ml
α-Hydroxy Alprazolam	50	Lorazepam	1,500
Alphrazolam	150	Lormetazepam	1,000
Bromazepam	800	Medazepam	2,000
Chlordiazepoxide	2,000	Nitrazepam	1,000
Clobazam	200	Nordiazepam	100
Clonazepam	4,000	Oxazepam	300
Delorazepam	6,000	Phenazepam	1,000
Diazepam	150	Prazepam	1,000
Estazolam	300	Temazepam	150
Flunitrazepam	1,000	Triazolam	1,500
Flurazepam	300		

BUPG 10 ng/ml

Compound	ng/ml	Compound	ng/ml
Buprenorphine	100	Norbuprenorphine	100
Buprenorphine Glucuronide	10	Norbuprenorphine Glucuronide	100

COC 300 ng/ml

Compound	ng/ml	Compound	ng/ml
Benzoylcegonine	150	Ecgonine	65,000

MDMA 500 ng/ml

Compound	ng/ml	Compound	ng/ml
d,l-3,4-MDA	2,000	d,l-3,4-MDMA	500
d,l-3,4-MDEA	250	d-Methamphetamine	50,000

MET 500 ng/ml

Compound	ng/ml	Compound	ng/ml
Ephedrine	10,000	d-Methamphetamine	500
p-Hydroxymethamphetamine	1,750	l-Methamphetamine	25,000
d,l-3,4-MDMA	1,000	Procaine	50,000
d,l-3,4-MDEA	20,000	Trimethobenzamide	75,000

MTD 300 ng/ml

Compound	ng/ml	Compound	ng/ml
Doxylamine	50,000	Methadone	300
2-Ethylidene-1,5-Dimethyl-1,3,3-Diphenylpyrrolidine	50,000	Pheniramine	75,000

OPI 300 ng/ml

Compound	ng/ml	Compound	ng/ml
6-Acetylmorphine	500	Hydrocodone	1,000
6-Acetylcodeine	600	Hydromorphone	400
Codeine	300	Morphine	300
Dihydrocodeine	500	Morphine-3-β-D-Glucuronide	500
Ethyl morphine	300	Nalorphine	5,000
Heroin	100		

OXY 100 ng/ml

Compound	ng/ml	Compound	ng/ml
6-Acetylcodeine	15,000	Oxymorphone	3,000
Codeine	5,000	Oxycodone	100
Dihydrocodeine	2,000	Hydromorphone Ethyl	25,000
Hydrocodone	300	Morphine	5,000

PCP 25 ng/ml

Compound	ng/ml	Compound	ng/ml
4-Hydroxy Phencyclidine	500	Phencyclidine	25
Metaphit	500	Phencyclidine Morpholine	50,000

PPX 300 ng/ml

Compound	ng/ml	Compound	ng/ml
Propoxyphene	300	Norpropoxyphene	500

TCA 1000 ng/ml

Compound	ng/ml	Compound	ng/ml
Amitriptyline	1,000	Nordoxepin	1,000
Clomipramine	7,500	Nortriptyline	1,000
Cyclobenzaprine	1,500	Perphenazine	50,000
Desipramine	750	Promazine	10,000
Doxepin	1,000	Protriptyline	350
Imipramine	750	Trimipramine	1,500

THC 50 ng/ml

Compound	ng/ml	Compound	ng/ml
Cannabidiol	100,000	11-Hydroxy-Δ9-THC	2,500
Cannabinol	50,000	Δ-8-Tetrahydrocannabinol	7,000
11-nor-Δ8-THC-9-COOH	50	Δ-9-Tetrahydrocannabinol	10,500
11-nor-Δ9-THC-9-COOH	50		

CONSUMER STUDY

A consumer study was conducted to determine the performance of the device when used by untrained, laypersons following only the instructions in the product labeling. A total of 153 participants read a total of 5460 assays during the study and 5228 of those 5460 assays (95.8%) was interpreted correctly. Each assay was tested by these participants using spiked solutions targeted to 0%, 25%, 50%, 75%, 125%, 150%, and 175% of the assay cutoff level.

INTERFERENCE

The following compounds were found not to cross-react when tested at concentrations up to 100 µg/ml (100,000 ng/ml).

Acetaminophen	Amitriptyline (except TCA assay)
Acetone	Amobarbital (except BAR assay)
Acetylsalicylic acid (Aspirin)	Amoxapine
6-Acetylcodeine (except OPI & OXY assay)	Amoxicillin
6-Acetylmorphine (except OPI assay)	Aprobarbital (except BAR assay)
Albumin	d-Amphetamine (except AMP assay)
Allobarbitol (except BAR assay)	l-Amphetamine (except AMP assay)
Alphenal (except BAR assay)	Ampicillin
Alprazolam (except BZO assay)	Apomorphine
Aspartame	l-Ascorbic Acid (Vitamin C)
Atropine	α-Hydroxy Alprazolam (except BZO assay)

Barbital (except BAR assay)	p-Hydroxymethamphetamine (except MET assay)
Benzilic acid	11-Hydroxy-Δ9-THC (except THC assay)
Benzocaine (Ethyl p-Aminobenzoate)	Ibuprofen
Benzoic acid	Imipramine (except TCA assay)
Benzoylcegonine (except COC assay)	d,l-Isoproterenol
Benzphetamine	Ketamine
Bilirubin	Lidocaine
Bromazepam (except BZO assay) d-	Lorazepam (except BZO assay)
Brompheniramine Buprenorphine (except BUPG assay)	Lormetazepam (except BZO assay)
Butabarbital (except BAR assay)	Medazepam (except BZO assay)
Butalbital (except BAR assay)	Meperidine
Butethal (except BAR assay)	Metaphit (except PCP assay)
Caffeine	Methadone (except MTD assay)
Cannabidiol (except THC assay)	d-Methamphetamine (except MET & MDMA assay)
Cannabinol (except THC assay)	l-Methamphetamine (except MET assay)
Chlordiazepoxide (except BZO assay)	Methaqualone
Chloroquine	Methoxyphenamine
d,l-Chlorpheniramine	(1R,2S) N-Methyl-Ephedrine
Chlorpromazine	2-Methylamine-Propiophenone
Cholesterol	d,l-3,4-Methylenedioxyamphetamine (except AMP & MDMA assays)
Clobazam (except BZO assay)	d,l-3,4-methylenedioxyethylamphet (except MET & MDMA assays)
Clomipramine (except TCA assay)	d,l-3,4-Methylenedioxyamphetamine (except MET & MDMA assays)
Clonazepam (except BZO assay)	Cocaine
Cocaine	Codeine (except OPI & OXY assays)
Codeine (except OPI & OXY assays)	Cortisone
Cortisone	l-Cotinine
l-Cotinine	Creatine
Creatine	Creatinine
Creatinine	Cyclobenzaprine (except TCA assay)
Cyclobenzaprine (except TCA assay)	Delorazepam (except BZO assay)
Delorazepam (except BZO assay)	Deoxycorticosterone
Deoxycorticosterone	Desipramine (except TCA assay)
Desipramine (except TCA assay)	Dextromethorphan
Dextromethorphan	Diazepam (except BZO assay)
Diazepam (except BZO assay)	Dihydrocodeine (except OPI & OXY assay)
Dihydrocodeine (except OPI & OXY assay)	4-Dimethylaminoantipyrine
4-Dimethylaminoantipyrine	Diphenhydramine
Diphenhydramine	Dopamine (3-Hydroxytyramine)
Dopamine (3-Hydroxytyramine)	Doxepin (except TCA assay)
Doxepin (except TCA assay)	Doxylamine (except MTD assay)
Doxylamine (except MTD assay)	Ecgonine (except COC assay)
Ecgonine (except COC assay)	Ecgonine Methyl Ester
Ecgonine Methyl Ester	l-Epinephrine
l-Epinephrine	d,l-Ephedrine (except MET assay)
d,l-Ephedrine (except MET assay)	Erythromycin
Erythromycin	Estazolam (except BZO assay)
Estazolam (except BZO assay)	β-Estradiol Estrone-3-Sulfate
β-Estradiol Estrone-3-Sulfate	Ethanol
Ethanol	Ethyl Morphine (except OPI & OXY assay)
Ethyl Morphine (except OPI & OXY assay)	Ethyl-p-aminobenzoate
Ethyl-p-aminobenzoate	2-Ethylidene-1,5-Dimethyl-1,3,3-Diphenylpyrrolidone (except MTD assay)
2-Ethylidene-1,5-Dimethyl-1,3,3-Diphenylpyrrolidone (except MTD assay)	Flunitrazepam (except BZO assay)
Flunitrazepam (except BZO assay)	Flurazepam (except BZO assay)
Flurazepam (except BZO assay)	Furosemide
Furosemide	Glucose
Glucose	Glutamic acid
Glutamic acid	Glutethimide
Glutethimide	Guaiacol Glyceryl Ether
Guaiacol Glyceryl Ether	Hemoglobin
Hemoglobin	Heroin (except OPI assay)
Heroin (except OPI assay)	Hippuric acid
Hippuric acid	Hydrochlorothiazide
Hydrochlorothiazide	Hydrocodone (except OPI & OXY assays)
Hydrocodone (except OPI & OXY assays)	Hydrocortisone
Hydrocortisone	Hydromorphone (except OPI & OXY assays)
Hydromorphone (except OPI & OXY assays)	4-Hydroxy Phencyclidine (except PCP assay)
4-Hydroxy Phencyclidine (except PCP assay)	

Quinidine	Thiamine
Quinine	Thioridazine
Ranitidine	Triazolam (<i>except BZO assay</i>)
Riboflavin	Trifluoperazine Trimethobenzamide
Salicylic acid	(<i>except MET</i>
Secobarbital (<i>except BAR assay</i>)	<i>assay</i>)
Serotonin	Trimipramine (<i>except TCA assay</i>)
Sertraline Sodium	Tryptamine
Chloride	d,l-Tryptophan
Sulfamethazine	Tyramine
Sulindac	d,l-Tyrosine
Temazepam (<i>except BZO assay</i>)	Uric Acid
Tetracycline	Verapamil
$\Delta 8$ -THC (<i>except THC assay</i>)	Zomepirac
$\Delta 9$ -THC (<i>except THC assay</i>)	
11-nor- $\Delta 8$ -THC-9-Carboxylic Acid	
(<i>except THC assay</i>)	

BIBLIOGRAPHY OF SUGGESTED READING

1. Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man, Biomedical Publications, Davis, CA, 1982.
2. Urine testing for Drugs of Abuse. National Institute on Drug Abuse (NIDA), Research Monograph 73, 1986.
3. Wong, R., The Current Status of Drug Testing in the US Workforce, Am. Clin. Lab., 2002; 21(1): 21-23
4. Wong, R., The Effect of Adulterants on Urine Screen for Drugs of Abuse: Detection by an On-site Dipstick Device, Am. Clin. Lab., 2002; 21(3); 14-18
5. Young, D.S. et. al., Clinical Chemistry, 21 (9), 1975.
6. U.S. Dept. of Transportation, Procedures for Transportation Workplace Drug and Alcohol Testing Programs. Federal Register, 1999 Dec.; 64(236); 69076
7. U.S. Dept. of Health and Human Services, Mandatory Guidelines for Federal Workplace Drug Testing Programs. Federal Register, 2001 Aug.; 66(162): 43876
8. Fed. Register, Department of Health and Human Services, Mandatory Guidelines for Federal Workplace Drug Testing Programs, 53, 69, 11970-11979, 1988.
9. Liu, Ray H. and Goldberger, Bruce A., Handbook of Workplace Drug Testing, AACC Press (1995).
10. Gilman, A. G. and Goodman, L. S., The Pharmacological Basis of Therapeutics, eds. MacMillan Publishing, New York, NY, 1980.
11. McBay, A.J. Clin. Chem. 33, 33B-40B, 1987.
12. Ringsrud, K.M and Linne, J.J., Urinalysis and Body Fluids, A color Text and Atlas, Mosby-Year Book, Inc., 1995.
13. Baselt RC. Disposition of toxic Drugs and chemicals in Man. 6th Ed. Biomedical Publ., Davis, CA. 2002; 129

Manufactured for:
 Noble Medical, Inc.
 Brookfield, WI 53045
 Toll-free: 1-877-836-5713

Part No.: PI-X14-NBCA-13A-B Rev: A02, 06/2015